Literature DB >> 16880142

Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.

David T Yang1, Michele M Flanders, Hyunhee Kim, George M Rodgers.   

Abstract

High levels of factor XI have been implicated as a risk factor for deep venous thrombosis and possibly cardiovascular disease; however, the relationship between elevated factor XI activity and stroke has yet to be established. We retrospectively evaluated factor XI activity, factor XI antigen, and high-sensitivity C-reactive protein (hs-CRP) values in samples from 65 patients with stroke, 13 with transient ischemic attack (TIA), and 17 with venous thrombosis, younger than 55 years with normal prothrombin and partial thromboplastin times who underwent evaluation for a hypercoagulable state. Factor XI activity levels were more than normal in 22% of patients with stroke or TIA and 18% of patients with venous thrombosis, producing odds ratios of 5.3 and 4.1 for stroke or TIA and venous thrombosis, respectively. Factor XI activity levels correlate with factor XI antigen levels by Deming regression analysis (slope, 1.3; R = 0.667) and a lack of correlation of both with hs-CRP suggests that factor XI is not an acute phase reactant. Our findings suggest an association between elevated factor XI activity and stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880142     DOI: 10.1309/QC259F09UNMKVP0R

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  42 in total

Review 1.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

2.  Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  M Fareed K Suri; Kazumasa Yamagishi; Nena Aleksic; Peter J Hannan; Aaron R Folsom
Journal:  Cerebrovasc Dis       Date:  2010-03-19       Impact factor: 2.762

3.  Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis.

Authors:  Erik I Tucker; Norah G Verbout; Philberta Y Leung; Sawan Hurst; Owen J T McCarty; David Gailani; András Gruber
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

Review 4.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 5.  Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?

Authors:  Becky Woodruff; Bruce Sullenger; Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

Review 6.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

7.  Relation of coagulation factor XI with incident coronary heart disease and stroke: the Cardiovascular Health Study.

Authors:  Duke Appiah; Oluwaseun E Fashanu; Susa R Heckbert; Mary Cushman; Bruce M Psaty; Aaron R Folsom
Journal:  Blood Coagul Fibrinolysis       Date:  2017-07       Impact factor: 1.276

8.  Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.

Authors:  Anetta Undas; Agnieszka Slowik; Matthew Gissel; Kenneth G Mann; Saulius Butenas
Journal:  Eur J Clin Invest       Date:  2011-06-27       Impact factor: 4.686

9.  Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Aaron R Folsom; Kristen M George; Duke Appiah
Journal:  Atherosclerosis       Date:  2015-09-10       Impact factor: 5.162

Review 10.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.